Drug intelligence / Profile preview

NORDBIOTIC ImmunoVIR

Development stage: Unknown
Lead developer: Nordic Biotic
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

NORDBIOTIC ImmunoVIR is a probiotic dietary supplement developed by Nordic Biotic, consisting of a formulation of five bacterial strains. Administered orally, it is designed to support immune health and respiratory wellness, particularly during viral seasons. The product functions by modulating host immune responses and microbiome-immune interactions. Clinical data published in 2024 indicates that the formulation can reduce the duration and severity of COVID-19 symptoms, enhance humoral immune responses to viral antigens, and accelerate recovery from post-viral fatigue and anxiety. It is positioned as a clinically validated solution for immune support rather than a traditional pharmaceutical drug.

Brand names: NORDBIOTIC ImmunoVIR
Other names: NORDBIOTIC Immunovir

Beyond the preview

Go deeper on NORDBIOTIC ImmunoVIR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NORDBIOTIC ImmunoVIR.

Explore the full profile